Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > LATEST
LATEST
-
REGULATORY LDP Lawmakers Seek Separate Drug Pricing Measures for Inflation
July 2, 2026
-
REGULATORY Govt’s Honebuto Draft Confirms FY2027 Off-Year Drug Price Revision
July 1, 2026
-
ACADEMIA NEJM Retracts Paper on Tavneos’ Pivotal Study
July 1, 2026
-
REGULATORY Govt Presents Growth Strategy Draft Ahead of July Approval
July 1, 2026
-
BUSINESS Ultragenyx Seeks Japan Approval for GSDIa Gene Therapy
July 1, 2026
-
COMMENTARY New Generic Listings Plunge, Industry Heads for a Shakeout
July 1, 2026
-
BUSINESS Specialist Hails Wegovy as “Game Changer” for MASH Treatment
July 1, 2026
-
REGULATORY Japan Moves to Add Ceftriaxone to Economic Security List
July 1, 2026
-
REGULATORY LDP Group Submits Honebuto Proposal, Urges Pediatric Cancer Platform
July 1, 2026
-
BUSINESS Alfresa Boosts Stake in ENT Cell Sheet Startup
July 1, 2026
-
BUSINESS Eisai, UCL Renew Neuroscience Alliance to 2030
July 1, 2026
-
BUSINESS Asahi Kasei Nabs Japan Rights to Additional Empaveli Indications
July 1, 2026
-
BUSINESS Viatris Eyes Japan Filing This Year for IgAN Drug
July 1, 2026
-
REGULATORY Lower House Clears Immunization Act Revision
July 1, 2026
-
REGULATORY LDP Cautious over Ishin’s GDP-Linked Healthcare Spending Proposal
July 1, 2026
ページ
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
The development of Boehringer Ingelheim’s survodutide is gathering pace, putting the GLP-1/glucagon receptor agonist in contention to become the next…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…